Navigation Links
Step forward in research into new treatments for brain edema
Date:3/19/2012

Cerebral edemas are accumulations of fluid into the intra- or extracellular spaces of the brain and it can result from several factors such as stroke or head trauma, among others.

Cerebral edema is a serious problem in neurology. While in other organs swelling does not lead to an urgent situation, in the brain it leads to coma and death. Although there are therapeutic solutions such as surgery, more effective treatments are needed.

Megalencephalic leukoencephalopathy with subcortical cysts (MLC) is a rare type of leukodystrophy (affects the white matter) of genetic origin. MLC can be considered as a model of chronic edema, as patients suffering from birth a high accumulation of water.

A study of the pathophysiology of this rare disease has uncovered one mechanism that destabilizes the homeostatic balance of brain cells causing edema. This study is published in the latest issue of the journal Neuron. The journal accompanies the paper with a commentary of the editor and an explanatory video on its website.

Researchers from IDIBELL, the University of Barcelona (UB) and CIBERER (Spanish Network Research Centre on Rare Diseases) have found that one function of the protein GlialCAM, which is genetically altered in patients with MLC, is to regulate the activity of the channel that allows the passage of chloride ions between brain cells to regulate ion and fluid balance.

When this protein is lacked, the channel is not working properly and the fluid builds up in the brain glial cells forming edema.

Raul Estevez, director of this work, and Virginia Nunes, a partner of the study, believe that the importance of this finding is twofold. "On one hand", explains Virginia Nunes, "it allows us to better understand the pathophysiology of this disease minority" and "on the other hand", Raul Estevez continues, "we have identified a mechanism that can open doors to treatments based on the activation of this channel to restore homeostatic balance and perhaps treat brain edema in general."

Both researchers agree to say that this case demonstrates that the investigation of a rare disease that affects a small proportion of the population can serve as a model to identify mechanisms to think of new treatments for common diseases.

MLC Leukodistophy

Megalencephalic Leukoencephalopathy with subcortical cysts (MLC) is a rare type of leukodystrophy that appears during the first year of life, characterized by macrocephaly (oversized head). A few years later, it appears a slow neurological deterioration with ataxia (lack of motor coordination) and spasms. Magnetic resonance techniques revealed inflammation of the cerebral white matter and subcortical cysts, particularly in the anterior temporal regions.

In the 75% of MLC patients it has been identified mutations in the gene MLC1, which cause the disease. Virginia Nunes and Raul Estevez have recently identified a second gene causing MLC, named GlialCAM.

In the present study they have been identified precisely a GlialCAM protein as an ion channel subunit chloride that allows its entering and exiting the brain so that the cells can regulate the homeostatic balance.


'/>"/>

Contact: Arantxa Mena
comunicacio@idibell.cat
IDIBELL-Bellvitge Biomedical Research Institute
Source:Eurekalert

Related biology news :

1. New technique is quantum leap forward in understanding proteins
2. How to move agriculture forward with limited water
3. Moving gene therapy forward with mobile DNA
4. Clinical trials for shingles drug take an important step forward
5. Another JDRF partner moves research forward with collaboration agreement for diabetes treatment
6. Step forward for nanotechnology: Controlled movement of molecules
7. First adhere, then detach and glide forward
8. Meteosat Third Generation takes a step forward
9. A fat forward research tool
10. CAKE offers way forward for climate change adaptation
11. Growing drought-tolerant crops inching forward
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)... 2017  Trovagene, Inc. (NASDAQ: TROV ), ... announced that it has signed agreements with seven strategic ... Middle East for commercialization of ... first wave of international distribution agreements for Trovagene,s CLIA ... The initial partners will introduce Trovagene,s liquid ...
(Date:1/12/2017)... PUNE, India , January 12, 2017 A new ... - 2022," projects that the global biometric technology market is expected to generate revenue ... 2022. Continue Reading ... ...      (Logo: http://photos.prnewswire.com/prnh/20140911/647229) ...
(Date:1/11/2017)... 2017  Michael Johnson, co-founder of Visikol Inc. a company originally ... been named to the elite "Forbes 30 Under 30" list in ... people in 20 fields nationwide to be recognized as a leader ... were selected. ... is currently a PhD candidate at Rutgers University. ...
Breaking Biology News(10 mins):
(Date:1/11/2017)... ... January 11, 2017 , ... With sepsis claiming ... more than $23.7 billion, healthcare systems are looking to provide better and ... common sepsis-causing pathogens are bacteria and the yeast pathogen Candida, which can lead ...
(Date:1/11/2017)... ... January 11, 2017 , ... IsoPlexis ... response analysis platform to measure the proteomic function of individual cells in patients, ... Research (SBIR) grant from the National Institute on Aging of the National Institutes ...
(Date:1/11/2017)... ... January 11, 2017 , ... Back pain relief technology ... Shots and No Surgery for positive back pain relief for WAR members. , This ... worldwide and could be life changing for millions suffering from chronic back pain. , ...
(Date:1/11/2017)... 11, 2017 AnaptysBio, Inc., a clinical-stage ... on unmet medical needs in inflammation, today announced ... chief financial officer.  Mr. Piscitelli will play a ... as overseeing the company,s accounting and SEC reporting ... welcome Dominic to the senior management team at ...
Breaking Biology Technology: